ACRV — Acrivon Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Acrivon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.2 | -31.2 | -60.4 | -80.6 | -77.9 |
| Depreciation | |||||
| Non-Cash Items | 1.9 | 2.22 | 9.07 | 11.4 | 15.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.328 | -1.53 | 8.14 | 2.44 | -2.43 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -14 | -30.1 | -42.6 | -65.7 | -63.7 |
| Capital Expenditures | -0.238 | -2.17 | -1.29 | -2.77 | -1.67 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -140 | 52 | -49 | 67.8 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.238 | -142 | 50.7 | -51.8 | 66.1 |
| Financing Cash Flow Items | — | 99.8 | -1.3 | -2.52 | -0.75 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 112 | 102 | -1.55 | 121 | -0.749 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 98 | -70.1 | 6.52 | 3.59 | 1.69 |